期刊
MOLECULES
卷 27, 期 19, 页码 -出版社
MDPI
DOI: 10.3390/molecules27196270
关键词
cholesterol-lowering ability; PTL; hypercholesterolemia; drug screening
资金
- Youth Innovation Team Talent Introduction Program of Shandong Province [20190164]
- Natural Science Foundation of Shandong Province [ZR2021QH212, ZR2020MH369]
Parthenolide (PTL), a naturally occurring small molecule from Tanacetum parthenium, has shown potential in lowering cholesterol levels by inhibiting cellular uptake of cholesterol. Its interaction with NPC1L1 supports its potential as a therapeutic inhibitor for hypercholesterolemia.
Elevated cholesterol significantly increases the risk of developing atherosclerosis and coronary heart disease. The key to treating hypercholesterolemia is lowering plasma cholesterol levels. There have been no studies on the cholesterol-lowering potential of parthenolide (PTL), a naturally occurring small molecule from Tanacetum parthenium. Here, we first put forth PTL's cholesterol-lowering ability to inhibit cellular uptake of cholesterol in a dose-dependent manner. Its performance was on par with the positive control drug, ezetimibe. Niemann-Pick C1 Like-1 (NPC1L1) has been identified as a potential therapeutic target for hypercholesterolemia. The interaction of PTL with NPC1L1 could be explained by the results of molecular docking and filipin staining further reinforces this hypothesis. Furthermore, PTL reduced the expression of NPC1L1 in HepG2 cells in a concentration-dependent manner, which suggests that PTL functions as a potential NPC1L1 inhibitor with therapeutic potential for hypercholesterolemia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据